• Activity INFORMATION

  Overview

  While much of the industry’s attention in 2021 was focused on FDA decisions about COVID vaccines and related therapies, a total of 50 new drugs were approved in 2021, outpacing the 10-year average for FDA drug approvals. This session provides a broad overview of the drugs approved in 2021, which includes significant growth in monoclonal antibody approvals. This session is designed to be a cursory overview of new approvals, bringing forward the most actionable and relevant pieces for those practicing in today’s pharmacies. The session includes a look at the COVID related emergency use authorizations and approvals introduced in 2021 and reviews some of the more controversial decisions and challenges of the year.
  

  Handouts

  • Slide Document :   22080H01_2pp.pdf Download

  • Slide Document :   22080H01_6pp.pdf Download

  Financial Support By

  PharmCon

• Learning OBJECTIVES

  Pharmacist

  For selected new medications approved in 2021, identify the burden-to-benefit ratio of therapy

  Identify important drug alerts by the FDA (Public Health Advisories) and implications for patient care

  Recognize the approved indication, common adverse effects, and drug interactions for new drugs approved by the FDA in 2021

  Pharmacy Technician

  For selected new medications approved in 2021, identify the burden-to-benefit ratio of therapy

  Recognize the approved indication, common adverse effects, and drug interactions for new drugs approved by the FDA in 2021

  Identify important drug alerts by the FDA (Public Health Advisories) and implications for patient care

  Nurse

  For selected new medications approved in 2021, identify the burden-to-benefit ratio of therapy

  Identify important drug alerts by the FDA (Public Health Advisories) and implications for patient care

  Recognize the approved indication, common adverse effects, and drug interactions for new drugs approved by the FDA in 2021

• Activity ACCREDITATION

  Activity Type

  Knowledge

  CE Broker

  20-919597

  Universal Activity Number

  Pharmacist 0798-0000-22-080-H01-P
  Pharmacy Technician 0798-0000-22-080-H01-T
  Nurse 0798-0000-22-080-H01-N
  

  PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

  PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

  In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

• Activity INSTRUCTION

  Faculty

  Mary Lynn  McPherson, PharmD, PhD, BCPS, FAAHPM Professor and Executive Director, Advanced Post-Graduate Education in Palliative Care, University of Maryland School of Pharmacy

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).